Nanoparticle drug conjugates
US10111963B2 · kind B2 · utility
9Cited by
28References
34Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 27, 2015 |
| Grant date | Oct 30, 2018 |
| Priority date | — |
| Expiry date | May 27, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.